Improvement Effect of Resistant Maltodextrin in Humans with Metabolic Syndrome by Continuous Administration

• Published in: Journal of Nutritional Science and Vitaminology Vol. 58; no. 6; pp. 423 - 430
• Main Authors: YAMAMOTO, Takushi, HASHIZUME, Chieko, KISHIMOTO, Yuka, KANAHORI, Sumiko, OKUMA, Kazuhiro, YAMAMOTO, Kunio
• Format: Journal Article
• Language: English
• Published: Tokyo Center for Academic Publications Japan 2012
• Subjects: Aged; Asian Continental Ancestry Group; Biological and medical sciences; Blood Glucose - analysis; Blood Glucose - drug effects; Body Composition - drug effects; Cholesterol - blood; Double-Blind Method; Feeding. Feeding behavior; Female; Fundamental and applied biological sciences. Psychology; glucose and lipid metabolism; Humans; Image Processing, Computer-Assisted; Insulin - blood; Intra-Abdominal Fat - drug effects; Intra-Abdominal Fat - metabolism; Leptin - blood; Male; Medical sciences; Metabolic diseases; metabolic syndrome; Metabolic Syndrome - drug therapy; Middle Aged; Miscellaneous; Obesity - drug therapy; Other metabolic disorders; Polysaccharides - administration & dosage; resistant maltodextrin; Risk Factors; soluble dietary fiber; Triglycerides - blood; Vertebrates: anatomy and physiology, studies on body, several organs or systems; visceral fat; Endocrinopathy; Visceral fat; Human; resistant maltodextrin; Metabolic diseases; Cardiovascular disease; Lipids; Glucose; Metabolism; Metabolic syndrome; soluble dietary fiber; Maltodextrin; glucose and lipid metabolism; Dietary fiber
• ISSN: 0301-4800; 1881-7742; 1881-7742
• DOI: 10.3177/jnsv.58.423

Resistant maltodextrin (RMD) is a soluble dietary fiber ingredient whose physiological functions are well recognized in Foods for Specified Health Use (FOSHU) for maintaining healthy intestinal regularity, blood glucose levels, and serum lipids. However, its efficacy on combined health risks—metabolic syndrome—was not studied yet. In this study the efficacy of RMD on humans with metabolic syndrome was investigated. A randomized double-blind placebo-controlled parallel-group trial was conducted. Thirty subjects with metabolic syndrome were randomly allocated into 2 groups and took either tea containing 9 g of RMD (treatment group) or placebo tea at three mealtimes daily for 12 wk. Blood was collected and body fat was scanned periodically. In the RMD treatment group, waist circumference, visceral fat area, fasting blood glucose, HOMA-R and serum triacylglycerol (TG) were significantly decreased compared to baseline, and significant time-by-treatment interaction was observed for waist circumference, visceral fat area, HOMA-R and serum TG (p=0.044, p=0.012, p=0.032, and p=0.049, respectively). The change ratio of visceral fat area showed negative statistical correlation with the baseline value (p=0.033), suggesting that efficacy of RMD was emphasized in the subjects having a larger visceral fat area. After the 12-wk RMD treatment, the total number of metabolic syndrome risk factors decreased to 20 from 32 with 2 subjects having no risks, while that of the placebo group decreased to 25 from 32. These findings suggest that continuous ingestion of RMD may improve the risk factors of metabolic syndrome by reducing visceral fat and improving glucose and lipid metabolism.